Literature DB >> 9871656

Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides.

R T Lum1, M G Nelson, A Joly, A G Horsma, G Lee, S M Meyer, M M Wick, S R Schow.   

Abstract

Potent inhibitors of the 20S proteasome that contain a novel indanone head group coupled to di and tripeptides are described. These compounds are the first proteasome inhibitors have demonstrated high selectivity for the chymotrypsin-like activity of the 20S proteasome.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9871656     DOI： 10.1016/s0960-894x(98)00015-8

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  7 in total

Review 1.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

Review 2.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27

Review 3.  Proteasome inhibition: a new strategy in cancer treatment.

Authors:  J Adams; V J Palombella; P J Elliott
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

4.  Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.

Authors:  Christopher Blackburn; Kenneth M Gigstad; Paul Hales; Khristofer Garcia; Matthew Jones; Frank J Bruzzese; Cynthia Barrett; Jane X Liu; Teresa A Soucy; Darshan S Sappal; Nancy Bump; Edward J Olhava; Paul Fleming; Lawrence R Dick; Christopher Tsu; Michael D Sintchak; Jonathan L Blank
Journal:  Biochem J       Date:  2010-09-15       Impact factor: 3.857

5.  Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome.

Authors:  Sarmad Sahiel Hindo; Michael Frezza; Dajena Tomco; Mary Jane Heeg; Lew Hryhorczuk; Bruce R McGarvey; Q Ping Dou; Cláudio N Verani
Journal:  Eur J Med Chem       Date:  2009-05-24       Impact factor: 6.514

Review 6.  The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.

Authors:  Owen A O'Connor
Journal:  Curr Treat Options Oncol       Date:  2004-08

7.  Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells.

Authors:  Carlos García-Echeverría
Journal:  Int J Pept Res Ther       Date:  2006-03-04       Impact factor: 1.931
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.